Early postoperative measurement of growth hormone level for prognosis of surgical outcomes in acromegaly

Cover Page

Cite item

Full Text

Abstract

Aim. To investigate the value of 24 hours post-surgery measurement of growth hormone (GH) level for prognosis of surgical outcomes in acromegaly.

Materials and methods. A prospective cohort study included 45 patients with newly diagnosed acromegaly. The degree of parasellar extension was measured on the preoperative sellar magnetic resonance imaging according to the Knosp’s classification. All patients underwent a transsphenoid adenomectomy performed by one neurosurgeon. Basal GH level was measured at 24 hours after surgery. The efficacy of transsphenoidal adenomectomy evaluated at 12 months after surgery.

Results. Acromegaly remission was achieved in 19 (42%) of 45 patients at 12 months after surgery. Pituitary microadenomas and the absence of paracellular invasion, corresponding to Knosp Grade 0–2, had low prognostic value for long-term remission due to low sensitivity (31.6%) and low specificity (38.5%), respectively. The highest prognostic value for acromegaly remission was showed for 24 hours post-surgery GH level with cut-off <1.30 ng/ml with sensitivity of 96.2% (95% confidence interval 81.1–99.8%) and specificity of 84.2% (95% confidence interval 62.4–94.4%).

Conclusion. The study demonstrated the possibility of using GH level at 24 after surgery as a predictor for acromegaly remission. GH level <1.30 ng/ml at 24 hours after surgery showed better predictive value for long-term remission compared with the presence of microadenomas and Knosp Grade 0–2. The absence of decrease of GH level on the first day after surgery may serve as a reason for more close monitoring of patients in the postoperative period. Further studies in a larger number of observers are required to confirm our findings.

About the authors

A. I. Tsiberkin

Almazov National Medical Research Center

Author for correspondence.
Email: tsibern1@gmail.com
ORCID iD: 0000-0001-6587-4313

врач-эндокринолог, мл. науч. сотр. НИЛ нейроэндокринологии

Russian Federation, Saint Petersburg

U. A. Tsoy

Almazov National Medical Research Center

Email: tsibern1@gmail.com
ORCID iD: 0000-0003-4013-4831

к.м.н., зав. НИЛ нейроэндокринологии

Russian Federation, Saint Petersburg

V. Yu. Cherebillo

Almazov National Medical Research Center

Email: tsibern1@gmail.com
ORCID iD: 0000-0001-6803-9954

д.м.н., проф., врач-нейрохирург отд-ния нейрохирургии №6

Russian Federation, Saint Petersburg

A. V. Polezhaev

Almazov National Medical Research Center

Email: tsibern1@gmail.com
ORCID iD: 0000-0001-9450-1516

к.м.н., науч. сотр. НИЛ нейроэндокринологии

Russian Federation, Saint Petersburg

N. V. Kuritsyna

Almazov National Medical Research Center

Email: tsibern1@gmail.com
ORCID iD: 0000-0003-1337-1719

врач-эндокринолог ЛРК-1

Russian Federation, Saint Petersburg

A. A. Paltsev

Almazov National Medical Research Center

Email: tsibern1@gmail.com
ORCID iD: 0000-0002-9966-2965

к.м.н., зав. отд-нием нейрохирургии №6

Russian Federation, Saint Petersburg

A. V. Alkhazishvili

Almazov National Medical Research Center

Email: tsibern1@gmail.com
ORCID iD: 0000-0002-7250-6786

аспирант каф. лучевой диагностики и медицинской визуализации, врач-рентгенолог детского ЛРК

Russian Federation, Saint Petersburg

E. N. Grineva

Almazov National Medical Research Center

Email: tsibern1@gmail.com
ORCID iD: 0000-0003-0042-7680

д.м.н., проф., дир. Института эндокринологии

Russian Federation, Saint Petersburg

References

  1. Dineen R, Stewart PM, Sherlock M. Acromegaly. QJM. 2017;110(7):411-20. doi: 10.1093/qjmed/hcw004
  2. Дедов И.И., Молитвослова Н.Н., Рожинская Л.Я., Мельниченко Г.А. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения акромегалии. Проблемы эндокринологии. 2013;59(6):4-18 [Dedov II, Molitvoslova NN, Rozhinskaya LYa, Melnichenko GA. Federal clinical guidelines for the clinic, diagnosis, differential diagnosis and treatment of acromegaly. Problemy ehndokrinologii. 2013;59(6):4-18 (In Russ.)]. doi: 10.14341/probl20135964-18
  3. Starnoni D, Daniel RT, Marino L, et al. Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien). 2016;158(11):2109-21. doi: 10.1007/s00701-016-2903-4
  4. Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol. 2005;153(2):187-93. doi: 10.1530/eje.1.01968
  5. Starke RM, Raper DM, Payne SC, et al. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013;98(8):3190-8. doi: 10.1210/jc.2013-1036
  6. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51. doi: 10.1210/jc.2014-2700
  7. Астафьева Л.И., Калинин П.Л., Кадашев Б.А. Современная диагностика и послеоперационный мониторинг пациентов с акромегалией в условиях нейрохирургической клиники. Вопр. нейрохирургии им. Н.Н. Бурденко. 2017;81(1):58-62 [Astaf’eva LI, Kalinin PL, Kadashev BA. Modern diagnosis and postoperative monitoring of acromegaly patients at a neurosurgical clinic. Voprosy neirokhirurgii im. N.N. Burdenko. 2019;83(1):98-104 (In Russ.)]. doi: 10.17116/neiro201780758-62
  8. Kim EH, Oh MC, Lee EJ, Kim SH. Predicting Long-term Remission by Measuring Immediate Postoperative Growth Hormone Levels and Oral Glucose Tolerance Test in Acromegaly. Neurosurgery. 2012;70(5):1106-13. doi: 10.1227/neu.0b013e31823f5c16
  9. Dutta P, Korbonits M, Sachdeva N, et al. Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly? Neurol India. 2016;64(2):252-8. doi: 10.4103/0028-3886.177622
  10. Rotermund R, Burkhardt T, Rohani Z, et al. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly. Growth Horm IGF Res. 2018;41:64-70. doi: 10.1016/j.ghir.2018.03.002
  11. Sarkar S, Jacob KS, Pratheesh R, et al. Transsphenoidal surgery for acromegaly: predicting remission with early postoperative growth hormone assays. Acta Neurochirurgica. 2014;156(7):1379-87. doi: 10.1007/s00701-014-2098-5
  12. Dal J, Feldt-Rasmussen U, Andersen M, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016;175(3):181-90. doi: 10.1530/EJE-16-0117
  13. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993;33(4):610-7. doi: 10.1227/00006123-199310000-00008
  14. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-8. doi: 10.1210/jc.2009-2670
  15. Циберкин А.И., Цой У.А., Черебилло В.Ю. и др. Оценка результатов транссфеноидальной аденомэктомии при акромегалии с применением различных критериев ремиссии. Вопр. нейрохирургии им. Н.Н. Бурденко. 2019;83(1):98-104 [Tsiberkin AI, Tsoy UA, Cherebillo VY, et al. Evaluation of transsphenoidal adenomectomy outcomes in acromegaly using different remission criteria. Voprosy neirokhirurgii im. N.N. Burdenko. 2019;83(1):98-104 (In Russ.)]. doi: 10.17116/neiro20198301198
  16. Babu H, Ortega A, Nuno M, et al. Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. Neurosurgery. 2017;81(2):357-66. doi: 10.1093/neuros/nyx020
  17. Hazer DB, Işık S, Berker D, et al. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg. 2013;119(6):1467-77. doi: 10.3171/2013.8.JNS13224
  18. Feelders RA, Bidlingmaier M, Strasburger CJ, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab. 2005;90(12):6480-9. doi: 10.1210/jc.2005-0901
  19. Shin MS, Yu JH, Choi JH, et al. Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma. Neurosurgery. 2013;73(3):473-79. doi: 10.1227/01.neu.0000431480.87160.84
  20. Kristof RA, Neuloh G, Redel L, et al. Reliability of the oral glucose tolerance test in the early postoperative assessment of acromegaly remission. J Neurosurg. 2002;97(6):1282-6. doi: 10.3171/jns.2002.97.6.1282

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure 1. ROC curve for predicting remission of acromegaly based on the level of GY 24 hours after surgery.

Download (11KB)
3. Fig. 2. GH Level 24 hours after surgery in the remission and acromegaly persistence groups.

Download (10KB)

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies